Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

doi:10.1016/j.bone.2009.06.017

Paper

Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

Published Oct 1, 2009 · Yuichiro Shimizu, Y. Tada, M. Yamauchi

Bone

Q1 SJR score

137

Citations

6

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Case Report

Highly Cited

Study Snapshot

Intravenous administration of saccharated ferric oxide can cause hypophosphatemia, a form of FGF23-related hypophosphatemia, with improved biochemical features when the treatment is stopped.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

Sign up to use Study Snapshot

References

Citations

A case report of autosomal dominant hypophosphatemic rickets due to a mutation in the FGF23 gene in an adult: diagnostic difficulties

Autosomal dominant hypophosphatemic rickets (ADHR) is a rare genetic rickets caused by mutations in the FGF23 gene, and genetic testing can help confirm hereditary forms and improve patient care.

Non-Classical Effects of FGF23: Molecular and Clinical Features

FGF23 plays a crucial role in phosphate metabolism and has pleiotropic effects in non-renal systems, including cardiovascular, immune, and metabolic systems.

Prevalence of FGF23 elevation in patients with hypophosphatemia.

Elevated FGF23 is present in 10.4% of patients with hypophosphatemia, suggesting that it should be integrated into routine evaluations to improve patient management.

The pathophysiology of hypophosphatemia.

Chronic hypophosphatemia can be categorized into four groups: FGF23 related, primary tubular dysfunction, vitamin D metabolism disturbance, and PTH1R mediated, with inherited and acquired forms.

Impact of Intravenous Iron Substitution on Serum Phosphate Levels and Bone Turnover Markers—An Open-Label Pilot Study

Intravenous iron substitution therapy with ferric carboxymaltose and iron sucrose leads to different adaptations in serum phosphate levels and bone turnover markers.

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia

The Medfrontier FGF23 assay is less accurate than the automated Determinar CL FGF23 assay in measuring intact FGF23 levels in healthy individuals and patients with chronic hypophosphatemia.

Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors

The combination of FDG-PET and FGF23VS is the most effective method for localizing phosphaturic mesenchymal tumors in patients with tumor-induced osteomalacia.